Abstracts tagged "rheumatoid arthritis (RA) and tolerance"

Abstract Number: 1064 • 2017 ACR/ARHP Annual Meeting
Characterization of Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor and Induction from Patients with Autoimmune Diseases
Hitoshi Hasegawa¹, Takuya Matsumoto¹, Endy Adnan², Jun Ishizaki¹, Koichiro Suemori¹ and Masaki Yasukawa¹, ¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ²Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan
Background/Purpose: Tolerogenic dendritic cells (tDCs) are a promising therapeutic tool for specific induction of immunological tolerance. Human tDCs can be generated ex vivo using various…
Abstract Number: 177 • 2016 ACR/ARHP Annual Meeting
Treatment with Dexamethasone and Monophosphoryl Lipid a Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers the Ability to Modulate CD4+ T Cell Responses
Paulina García-González^1,2, Oscar Neira³, Katina Schinnerling^1,2, Alejandro Sepúlveda-Gutiérrez⁴, Jaxaira Maggy^1,2, Lorena Hoyos^1,2, Rodrigo Morales^1,2, Gabriela Ubilla-Olguín^1,2, Ahmed Mehdi⁵, Hendrik Nel⁶, Lilian Soto^1,7, Bárbara Pesce^1,2, María Carmen Molina¹, Miguel Cuchacovich⁸, Milton Larrondo⁹, Diego Catalán^1,2, Catharien M. Hilkens¹⁰, Ranjeny Thomas¹¹, Ricardo Verdugo⁴ and Juan C. Aguillón^1,2, ¹Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile, Santiago, Chile, ²Millennium Institute on Immunology and Immunotherapy, Santiago, Chile, Santiago, Chile, ³Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, ⁴Programa de Genética Humana, ICBM, Universidad de Chile, Santiago, Chile, Santiago, Chile, ⁵Diamantina Institute, The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia, ⁶The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ⁷Unidad de Dolor, Hospital Clínico de la Universidad de Chile, Santiago, Chile, Santiago, Chile, ⁸Sección de Reumatología, Departamento de Medicina, Hospital Clínico de la Universidad de Chile, Santiago, Chile, ⁹Banco de Sangre, Hospital Clínico Universidad de Chile, Santiago, Chile, Santiago, Chile, ¹⁰Institute of Cellular Medicine, Musculoskeletal Research Group, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Newcastle upon Tyne,, United Kingdom, ¹¹The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia
Background/Purpose: Tolerogenic dendritic cells (TolDCs) are promising tools for therapy of autoimmune diseases such as rheumatoid arthritis (RA). Here we characterise TolDCs from RA patients…
Abstract Number: 950 • 2014 ACR/ARHP Annual Meeting
Multiple Mechanisms of Tolerance Characterize the Immune Response to Autologous Modified Dendritic Cells Exposed to Citrullinated Peptides in Patients with Rheumatoid Arthritis
Soi-Cheng Law¹, Hendrik Nel², Ahmed Mehdi², Kim-Anh Le Cao² and Ranjeny Thomas³, ¹Diamantina Institute, Univ of Queensland, Brisbane, Australia, ²Diamantina Institute, University of Queensland, Brisbane, Australia, ³Diamantina Institute, Univ of Queensland, Brisbane, QLD, Australia
Background/Purpose We carried out a phase I clinical trial of tolerising autologous peripheral blood DCs exposed to 4 citrullinated self-peptides (“Rheumavax”) in 29 HLA-DR shared…
Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting
Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort
Andra Negoescu¹, Elena Nikiphorou², Anshuman P. Malaviya³, Andrew Badcock³, John D. Fitzpatrick^3,4, Calum T. Goudie^3,4 and Andrew J. Ostor³, ¹Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge Medical School, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…
Abstract Number: 1148 • 2013 ACR/ARHP Annual Meeting
Autologous Tolerogenic Dendritic Cells In Rheumatoid and Inflammatory Arthritis
Gillian Bell¹, Amy Anderson², Julie Diboll¹, Rachel Harry², Elaine McColl³, Anne Dickinson⁴, Catharien Hilkens¹ and John Isaacs⁵, ¹Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Clinical Trials Unit, Institute of Health and Society, NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease which results from a breakdown of immune tolerance. Current therapies include traditional DMARDs, anti-TNF, B cell depleting…
Abstract Number: 2453 • 2012 ACR/ARHP Annual Meeting
The Role of Bob1 in Rheumatoid Arthritis: Potential Implications for Autoimmunity
Nataliya Yeremenko¹, Tineke Cantaert¹, Melissa N. van Tok², Ioana Gofita¹, Juan D. Canete³, Paul P. Tak⁴, Hergen Spits⁵ and Dominique L. Baeten⁴, ¹Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ³Arthritis Unit. Rheumatology Department, Hospital Clínic, Barcelona, Spain, ⁴Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Tytgat Institute for Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a prototypic autoimmune disease characterized by a prominent humoral autoimmunity. Of particular relevance is the local production of autoantibodies such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].